{"id":900402,"date":"2025-10-27T10:15:13","date_gmt":"2025-10-27T14:15:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\/"},"modified":"2025-10-27T10:15:13","modified_gmt":"2025-10-27T14:15:13","slug":"alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\/","title":{"rendered":"AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved &gt;90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026"},"content":{"rendered":"<h2>\nPost-conference recap highlights direct anti-tumor effects in epithelial and non-epithelioid mesothelioma models, &gt;90% tumor growth inhibition in vivo when TT-4 was combined with anti-PD-1, and superior monotherapy activity versus anti-PD-1 alone, reduced tumor PD-L1 correlated with decreased pCREB<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p id=\"isPasted\">Dover, DE, Oct.  27, 2025  (GLOBE NEWSWIRE) &#8212; AlphaTON Capital Corp (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r-NiUo2qOyvjy8XkjmJFmCowENBzJa2d9YAirfjgo3Yij2f2bwDi2mOvv9LuQpKRpc3plxlSi3RaBnki6TNj5IpAKX4jM0VdMbxgG0HIETsgLDsZI4LkYGo739Mam07L\" rel=\"nofollow\" target=\"_blank\">Nasdaq: ATON<\/a>) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics (Cyncado), today issued a recap of data presented on Saturday at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.<\/p>\n<p>The poster showed that\u00a0selective A2B receptor inhibition produces direct anti-tumor activity\u00a0in both epithelial and non-epithelioid mesothelioma models,\u00a0reduces tumor PD-L1 alongside decreased pCREB\u00a0in a human epithelioid mesothelioma cell system, and that\u00a0TT-4 monotherapy outperformed anti-PD-1\u00a0with\u00a0additional activity in combination.\u00a0TT-4 remains on track for first-patient dosing in Q1 2026.<\/p>\n<p>\u201cWith data now in the public domain showing\u00a0&gt;90% tumor growth inhibition for TT-4 plus anti-PD-1\u00a0and\u00a0TT-4 monotherapy outperforming anti-PD-1, we are executing toward first-patient dosing in Q1 2026,\u201d said\u00a0Peter Molloy, Chief Executive Officer of Cyncado Therapeutics. \u201cThese findings confirm that selective A2B inhibition exerts a direct anti-tumor effect across mesothelioma subtypes, reduces PD-L1, and drives immune activation consistent with durable response potential.<\/p>\n<p>\n        <b>Key takeaways from the poster<\/b>\n      <\/p>\n<ul type=\"none\">\n<li style=\"list-style-type:disc\">\n          <b>Direct tumor effect across subtypes<\/b>:\u00a0Blocking the\u00a0A2B receptor\u00a0produced\u00a0direct anti-tumor activity\u00a0in\u00a0both epithelial and non-epithelioid\u00a0mesothelioma models <\/li>\n<li style=\"list-style-type:disc\">\n          <b>Quantified anti-tumor activity<\/b>:\u00a0TT-4 + anti-PD-1 cut tumor growth by more than 90%\u00a0in vivo;\u00a0TT-4 alone outperformed anti-PD-1, with additive benefit in combination <\/li>\n<li style=\"list-style-type:disc\">\n          <b>Mechanistic evidence<\/b>:\u00a0Selective A2B inhibition decreased pCREB resulting in lowered PD-L1 expression in human mesothelioma spheroids; in murine models\u00a0TT-4\u00a0blocked NECA-induced pCREB and drove in-vivo tumor control <\/li>\n<li style=\"list-style-type:disc\">\n          <b>Immune activation<\/b>:\u00a0Combination therapy was associated with increased immune-effector infiltration, consistent with durable immune response <\/li>\n<li style=\"list-style-type:disc\">\n          <b>Advancing to clinic<\/b>:\u00a0TT-4 is\u00a0IND-enabled\u00a0and remains\u00a0on track for first-patient dosing in Q1 2026 <\/li>\n<\/ul>\n<p>\n        <b>Next steps<\/b>\n      <\/p>\n<p>Cyncado is using these findings to finalize clinical development plans for TT-4 in mesothelioma, with first patient dosing on track for Q1 2026.<\/p>\n<p>\n        <b>About AlphaTON Capital Corp<\/b>\n      <\/p>\n<p>AlphaTON Capital is a specialized digital asset treasury company focused on building and managing a strategic reserve of TON tokens and developing the Telegram ecosystem. The Company implements a comprehensive treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, AlphaTON Capital provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram&#8217;s billion user platform while maintaining the governance standards and reporting transparency of a Nasdaq-listed company.<\/p>\n<p>Led by Chief Executive Officer Brittany Kaiser and Chief Investment Officer, Enzo Villani, the company&#8217;s activities span network validation and staking operations, development of Telegram-based applications, and potential strategic investments in TON-based decentralized finance protocols, gaming platforms, and business applications. AlphaTON Capital Corp is incorporated in the British Virgin Islands and trades on Nasdaq under the ticker symbol\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2WvSrWevu5yLqsTe4mVkYxwAmYav3SAXiDpiwK2JYV3PlZ-jGvCtyHqO8erZ2ihyg48e4tNV7Ti48rE_YTpM8162X6m09P2KYFK_aAxnoLP_qEFfuwFutOxRsDeKOzZt\" rel=\"nofollow\" target=\"_blank\">ATON<\/a>.<\/p>\n<p>AlphaTON Capital, through its legacy business, is also advancing potentially first-in-class therapies that target known checkpoint resistance pathways to potentially achieve durable treatment response and improve quality of life for patients. AlphaTON Capital actively engages in the drug development process and provides strategic counsel to guide development of novel immunotherapy assets and asset combinations.<\/p>\n<p>\n        <b>About Cyncado Therapeutics<\/b>\n      <\/p>\n<p>Tarus Therapeutics, LLC (operating as Cyncado Therapeutics), a clinical stage, wholly owned subsidiary of AlphaTON Capital Corp, is developing potentially best-in-class small molecule adenosine receptor antagonists targeting A2A and A2B receptors to overcome immune suppression in oncology. The Company&#8217;s lead program, TT-4, is an oral, ultra-selective A2B receptor antagonist with an initial focus on mesothelioma, advancing toward first-patient dosing in Q1 2026. Cyncado is also developing dual-antagonist strategies designed to achieve comprehensive blockade of adenosine-mediated immune evasion, potentially unlocking synergistic anti-tumor effects and durable patient responses.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of applicable securities laws. All statements other than statements of historical fact, including statements regarding the Company&#8217;s business strategy, plans and objectives, future operations, clinical development timelines, TON ecosystem growth, therapeutic development outcomes, regulatory approvals, and statements preceded by, followed by, or including words such as &#8220;believe,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;targets,&#8221; or similar expressions, are forward-looking statements.<\/p>\n<p>These forward-looking statements are subject to substantial risks and uncertainties, including but not limited to: regarding clinical trial outcomes and regulatory approvals; uncertainty of the Company&#8217;s investment in TON and digital assets; regulatory and legal risks associated with digital assets; risks related to Telegram&#8217;s platform and the TON ecosystem; market volatility; competitive risks in both digital assets and therapeutics development; and other factors described in &#8220;Item 3 \u2013 Key Information-Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 20-F for the year ended March 31, 2025, and subsequent reports filed with the Securities and Exchange Commission.<\/p>\n<p>Although the Company believes the expectations reflected in these forward-looking statements are reasonable, actual results may differ materially. The Company undertakes no obligation to update publicly or revise any forward-looking statements, except as required by law.<\/p>\n<p>\n        <b>Contact Information<\/b>\n      <\/p>\n<p>\n        <b>Investor Relations<\/b><br \/>\n        <br \/>AlphaTON Capital Corp<br \/>AlphaTON@icrinc.com<br \/>(203) 682-8200<\/p>\n<p>\n        <b>Media Inquiries<\/b><br \/>\n        <br \/>Richard Laermer<br \/>RLM PR<br \/>AlphaTON@rlmpr.com<br \/>(212) 741-5106 X 216<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MjAxNSM3MjE0MzM2IzUwMDE1MDk1Mw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTMwMmNlMGQtMGIwZS00NGY2LWFlYjktMTQyYTMxZTdlMDMxLTUwMDE1MDk1My0yMDI1LTEwLTI3LWVu\/tiny\/AlphaTON-Capital.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Richard Laermer\r\nAlphaTON (at) rlmpr.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Post-conference recap highlights direct anti-tumor effects in epithelial and non-epithelioid mesothelioma models, &gt;90% tumor growth inhibition in vivo when TT-4 was combined with anti-PD-1, and superior monotherapy activity versus anti-PD-1 alone, reduced tumor PD-L1 correlated with decreased pCREB Dover, DE, Oct. 27, 2025 (GLOBE NEWSWIRE) &#8212; AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics (Cyncado), today issued a recap of data presented on Saturday at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. The poster showed that\u00a0selective A2B receptor inhibition produces direct anti-tumor activity\u00a0in both epithelial and non-epithelioid mesothelioma models,\u00a0reduces tumor PD-L1 alongside decreased pCREB\u00a0in a human epithelioid mesothelioma cell system, and that\u00a0TT-4 monotherapy outperformed anti-PD-1\u00a0with\u00a0additional &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved &gt;90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-900402","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved &gt;90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved &gt;90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Post-conference recap highlights direct anti-tumor effects in epithelial and non-epithelioid mesothelioma models, &gt;90% tumor growth inhibition in vivo when TT-4 was combined with anti-PD-1, and superior monotherapy activity versus anti-PD-1 alone, reduced tumor PD-L1 correlated with decreased pCREB Dover, DE, Oct. 27, 2025 (GLOBE NEWSWIRE) &#8212; AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics (Cyncado), today issued a recap of data presented on Saturday at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. The poster showed that\u00a0selective A2B receptor inhibition produces direct anti-tumor activity\u00a0in both epithelial and non-epithelioid mesothelioma models,\u00a0reduces tumor PD-L1 alongside decreased pCREB\u00a0in a human epithelioid mesothelioma cell system, and that\u00a0TT-4 monotherapy outperformed anti-PD-1\u00a0with\u00a0additional &hellip; Continue reading &quot;AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved &gt;90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-27T14:15:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MjAxNSM3MjE0MzM2IzUwMDE1MDk1Mw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved &gt;90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026\",\"datePublished\":\"2025-10-27T14:15:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\\\/\"},\"wordCount\":871,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU1MjAxNSM3MjE0MzM2IzUwMDE1MDk1Mw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\\\/\",\"name\":\"AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved &gt;90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU1MjAxNSM3MjE0MzM2IzUwMDE1MDk1Mw==\",\"datePublished\":\"2025-10-27T14:15:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU1MjAxNSM3MjE0MzM2IzUwMDE1MDk1Mw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU1MjAxNSM3MjE0MzM2IzUwMDE1MDk1Mw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved &gt;90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved &gt;90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\/","og_locale":"en_US","og_type":"article","og_title":"AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved &gt;90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026 - Market Newsdesk","og_description":"Post-conference recap highlights direct anti-tumor effects in epithelial and non-epithelioid mesothelioma models, &gt;90% tumor growth inhibition in vivo when TT-4 was combined with anti-PD-1, and superior monotherapy activity versus anti-PD-1 alone, reduced tumor PD-L1 correlated with decreased pCREB Dover, DE, Oct. 27, 2025 (GLOBE NEWSWIRE) &#8212; AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics (Cyncado), today issued a recap of data presented on Saturday at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. The poster showed that\u00a0selective A2B receptor inhibition produces direct anti-tumor activity\u00a0in both epithelial and non-epithelioid mesothelioma models,\u00a0reduces tumor PD-L1 alongside decreased pCREB\u00a0in a human epithelioid mesothelioma cell system, and that\u00a0TT-4 monotherapy outperformed anti-PD-1\u00a0with\u00a0additional &hellip; Continue reading \"AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved &gt;90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-27T14:15:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MjAxNSM3MjE0MzM2IzUwMDE1MDk1Mw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved &gt;90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026","datePublished":"2025-10-27T14:15:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\/"},"wordCount":871,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MjAxNSM3MjE0MzM2IzUwMDE1MDk1Mw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\/","name":"AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved &gt;90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MjAxNSM3MjE0MzM2IzUwMDE1MDk1Mw==","datePublished":"2025-10-27T14:15:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MjAxNSM3MjE0MzM2IzUwMDE1MDk1Mw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MjAxNSM3MjE0MzM2IzUwMDE1MDk1Mw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alphaton-nasdaqaton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved &gt;90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/900402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=900402"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/900402\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=900402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=900402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=900402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}